Calamos Advisors LLC Trims Stock Position in GeneDx Holdings Corp. (NASDAQ:WGS)

Calamos Advisors LLC trimmed its stake in GeneDx Holdings Corp. (NASDAQ:WGS) by 30.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 59,527 shares of the company’s stock after selling 25,475 shares during the period. Calamos Advisors LLC owned 0.22% of GeneDx worth $4,575,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. MCF Advisors LLC boosted its position in GeneDx by 107.7% during the 4th quarter. MCF Advisors LLC now owns 351 shares of the company’s stock valued at $27,000 after acquiring an additional 182 shares in the last quarter. CWM LLC purchased a new position in shares of GeneDx in the 3rd quarter valued at approximately $89,000. Evolution Wealth Advisors LLC bought a new stake in shares of GeneDx during the fourth quarter valued at approximately $202,000. PFG Investments LLC purchased a new stake in GeneDx in the fourth quarter worth $252,000. Finally, SG Americas Securities LLC bought a new position in GeneDx in the third quarter worth $198,000. Institutional investors own 61.72% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on WGS. Craig Hallum boosted their target price on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. TD Cowen boosted their price objective on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research note on Tuesday, January 7th. Wells Fargo & Company raised their target price on shares of GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 30th. Finally, The Goldman Sachs Group boosted their price target on GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $70.67.

GeneDx Stock Up 2.9 %

Shares of GeneDx stock opened at $72.02 on Wednesday. The company has a 50-day simple moving average of $77.91 and a two-hundred day simple moving average of $58.87. GeneDx Holdings Corp. has a 52-week low of $3.63 and a 52-week high of $98.87. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. The stock has a market capitalization of $1.98 billion, a PE ratio of -23.16 and a beta of 2.01.

Insider Buying and Selling

In other news, CEO Katherine Stueland sold 23,108 shares of the firm’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $70.48, for a total transaction of $1,628,651.84. Following the sale, the chief executive officer now owns 82,318 shares of the company’s stock, valued at $5,801,772.64. This trade represents a 21.92 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder School Of Medicine At Mo Icahn sold 126,782 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $70.78, for a total transaction of $8,973,629.96. Following the transaction, the insider now directly owns 2,719,692 shares of the company’s stock, valued at $192,499,799.76. The trade was a 4.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 363,669 shares of company stock worth $28,061,081 in the last three months. Insiders own 27.30% of the company’s stock.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.